このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

胎児および新生児の重症溶血性疾患のリスクのある妊娠におけるニポカリマブの研究 (HDFN) (AZALEA)

2026年11月2日 更新者:Janssen Research & Development, LLC

胎児および新生児の重症溶血性疾患(HDFN)のリスクのある妊娠におけるニポカリマブの有効性と安全性を評価するための第3相無作為化プラセボ対照二重盲検多施設共同研究

The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below normal levels while the baby is developing in the womb) with live neonates in pregnant participants at risk for severe hemolytic disease of the fetus and newborn.

調査の概要

研究の種類

介入

入学 (推定)

120

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Dublin、アイルランド、D01 P5W9
        • 募集
        • Rotunda Hospital
    • California
      • La Jolla、California、アメリカ、92037
        • 募集
        • University of California at San Diego
      • Los Angeles、California、アメリカ、90027
        • 募集
        • Kaiser Permanente Los Angeles Medical Center
      • Sacramento、California、アメリカ、95817
        • 募集
        • UC Davis School of Medicine
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • 募集
        • Childrens Hospital Colorado
    • Florida
      • Miami、Florida、アメリカ、33136
        • 募集
        • University of Miami
    • Illinois
      • Park Ridge、Illinois、アメリカ、60068
        • 募集
        • Advocate Children's Hospital
    • Indiana
      • Indianapolis、Indiana、アメリカ、46202
        • 一時停止
        • Riley Children s Hospital
    • Iowa
      • Iowa City、Iowa、アメリカ、52242
        • 募集
        • University of Iowa
    • Kentucky
      • Lexington、Kentucky、アメリカ、40536
        • 募集
        • University of Kentucky Medical Center
    • Maryland
      • Baltimore、Maryland、アメリカ、21287
        • 募集
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02115
        • 募集
        • Boston Childrens Hospital
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55404
        • 募集
        • Midwest Fetal Care Center
    • New York
      • New York、New York、アメリカ、10032
        • 募集
        • Columbia University Medical Center
    • North Carolina
      • Chapel Hill、North Carolina、アメリカ、27599-7516
        • 募集
        • University of North Carolina (UNC) - School of Medicine
    • Ohio
      • Cincinnati、Ohio、アメリカ、45267
        • 募集
        • University of Cincinnati
    • Oregon
      • Portland、Oregon、アメリカ、97239
        • 募集
        • Oregon Health and Science University
    • Pennsylvania
      • Allentown、Pennsylvania、アメリカ、18103-6218
        • 募集
        • Lehigh Valley Hospital
    • Texas
      • Austin、Texas、アメリカ、78723
        • 募集
        • University of Texas Dell Medical School Department of Women's Health
      • Galveston、Texas、アメリカ、77555
        • 募集
        • University Of Texas Medical Branch At Galveston
    • Utah
      • Murray、Utah、アメリカ、84107
        • 募集
        • Intermountain Medical Center
    • Virginia
      • Norfolk、Virginia、アメリカ、23507
        • 募集
        • Macon & Joan Brock Virginia Health Sciences at Old Dominion University
    • Washington
      • Seattle、Washington、アメリカ、98105
        • 募集
        • Seattle Children's Hospital
      • Buenos Aires、アルゼンチン、C1199
        • 募集
        • Hospital Italiano de Buenos Aires
      • Córdoba、アルゼンチン、X5016KEH
        • 募集
        • Hospital Privado Universitario De Cordoba
      • Birmingham、イギリス、B15 2TG
        • 募集
        • Birmingham Women's Hospital
      • Leeds、イギリス、LS9 7TF
        • 募集
        • Leeds Teaching Hospitals NHS Trust
      • London、イギリス、SE5 9RS
        • 募集
        • Kings College Hospital
      • London、イギリス、SW17 0QT
        • 募集
        • St Georges Hospital
      • Manchester、イギリス、M13 9WL
        • 募集
        • St.Mary's Hospital
      • Oxford、イギリス、OX3 9DU
        • 募集
        • John Radcliffe Hospital
      • Jerusalem、イスラエル、91240
        • 募集
        • Hadassah mount scopus
      • Petah Tikva、イスラエル、49100
        • 募集
        • Rabin Medical Center
      • Ramat Gan、イスラエル、5265601
        • 募集
        • The Chaim Sheba Medical Center
      • Roma、イタリア、00168
        • 募集
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Leiden、オランダ、2333 ZA
        • 募集
        • Leiden University Medical Center
      • South Brisbane、オーストラリア、4101
        • 募集
        • Mater Hospital Brisbane
      • Sydney、オーストラリア、2170
        • 募集
        • Liverpool Hospital
      • Graz、オーストリア、8036
        • 募集
        • Medizinische Universitaet Graz
      • Vienna、オーストリア、1090
        • 募集
        • Medizinische Universitaet Wien
    • British Columbia
      • Vancouver、British Columbia、カナダ、V6H 3N1
        • 募集
        • BC Women's Hospital University of British Columbia
    • Ontario
      • Toronto、Ontario、カナダ、M5G 1X5
        • 募集
        • Mount Sinai Hospital
    • Quebec
      • Montreal、Quebec、カナダ、H4A 3J1
        • 募集
        • McGill University Health Centre
      • Montreal、Quebec、カナダ、H3T 1C5
        • 募集
        • Centre Hospitalier Sainte Justine
      • Stockholm、スウェーデン、14186
        • 募集
        • Karolinska Universitetssjukhuset Huddinge
      • Barcelona、スペイン、08035
        • 募集
        • Hosp Univ Vall D Hebron
      • Madrid、スペイン、28046
        • 募集
        • Hosp. Univ. La Paz
      • Seville、スペイン、41013
        • 募集
        • Hosp. Virgen Del Rocio
      • Berlin、ドイツ、10117
        • 募集
        • Charite Universitaetsmedizin Berlin
      • Giessen、ドイツ、35392
        • 募集
        • Universitaetsklinikum Giessen und Marburg Standort Giessen
      • Hamburg、ドイツ、20251
        • 募集
        • Universitaetsklinikum Hamburg Eppendorf
      • Bron、フランス、69500
        • 募集
        • Hospices Civils de Lyon - Groupement Hospitalier Est - Hopital Femme Mere Enfant
      • Lille、フランス、59000
        • 募集
        • CHRU Lille
      • Paris、フランス、75012
        • 募集
        • Hopital Armand Trousseau
      • Belo Horizonte、ブラジル、30130 100
        • 募集
        • Faculdade de Medicina Universidade Federal de Minas Gerais
      • Goiânia、ブラジル、74605 020
        • 募集
        • Hospital das Clinicas - UFG
      • Recife、ブラジル、50070902
        • 募集
        • Instituto de Medicina Integral Professor Fernando Figueira
      • Rio de Janeiro、ブラジル、22281 100
        • 募集
        • IDOR - Regional Rio de Janeiro
      • São Paulo、ブラジル、05403-010
        • 募集
        • Hospital Das Clinicas Da Faculdade De Medicina Da USP
      • Brussels、ベルギー、1020
        • 募集
        • C.H.U. Brugmann
      • Leuven、ベルギー、3000
        • 募集
        • Universitair Ziekenhuis Leuven
      • Lodz、ポーランド、93 338
        • 募集
        • Instytut Centrum Zdrowia Matki Polki
      • Warsaw、ポーランド、01 211
        • 募集
        • Instytut Matki i Dziecka
      • Warsaw、ポーランド、02 507
        • 募集
        • Panstwowy Instytut Medyczny MSWiA w Warszawie
      • Fukuoka、日本、812 8582
        • 完了
        • Kyushu University Hospital
      • Gifu、日本、500-8717
        • 募集
        • Gifu Prefectural General Medical Center
      • Izumi-shi、日本、594-1101
        • 募集
        • Osaka Womens and Childrens Hospital
      • Sendai、日本、989-3126
        • 完了
        • Miyagi Childrens Hospital
      • Ōta-ku、日本、143-8541
        • 募集
        • Toho University Medical Center Omori Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~45年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  • Pregnant and an estimated gestational age (GA) (based on ultrasound dating) from Week 13^0/7 to Week 18^6/7 at randomization

  • History of severe Hemolytic Disease of the Fetus and Newborn (HDFN) in a prior pregnancy defined as documented:

    1. fetal anemia as result of HDFN or fetal hydrops as result of HDFN or received greater than or equal to (>=)1 IUT as a result of HDFN or
    2. fetal loss or neonatal death as a result of HDFN, with maternal alloantibody titers for Rhesus antigen D protein (RhD), Kell, Kell Rhesus antigen C protein (Rhc), Rhesus antigen E protein (RhE), or RhC antigen above the critical levels (anti-Kell >=4; other >=16) and evidence of an antigen-positive fetus
  • During the current pregnancy, presence of maternal alloantibody to RhD, Rhc, RhE, or RhC antigen with titers above the critical level (anti-Kell >= 4; other >=16) based on the designated central lab results at screening

  • Evidence of antigen-positivity corresponding to the current maternal alloantibody (RhD, Kell, Rhc, RhE, or RhC) confirmed by non-invasive antigen cell-free fetal DNA (cffDNA) performed at the central laboratory

  • Have screening lab test results within values within the study protocol-specified parameters: a) albumin >= lower limit of normal (LLN); b) alanine transaminase (AST) less than or equal to (<=) 2 × upper limit of normal (ULN); c) alanine transaminase (ALT) <=2 × ULN d) creatinine <=0.8 milligrams per deciliter (mg/dL), SI: <=70.7 micromole per liter (μmol/L), and Serum total immunoglobulins G (IgG) ≥ 600 mg/dL SI: >=6 g/L

  • Medically stable on the basis of physical examination, medical history, vital signs, 12-lead ECG, and clinical lab tests performed at screening

Exclusion Criteria:

  • Currently pregnant with a multiple gestation (twins or more)
  • Evidence of fetal anemia prior to randomization in the current pregnancy
  • History of severe preeclampsia prior to GA Week 34 or severe fetal growth restriction (estimated fetal weight <3rd percentile, based on local fetal growth normative standards) in a previous pregnancy
  • Current uncontrolled hypertension
  • History of myocardial infarction, unstable ischemic heart disease, or stroke
  • Has any confirmed or suspected clinical immunodeficiency syndrome or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
  • Has inflammatory or autoimmune diseases requiring immunosuppressive therapies that may jeopardize the safety of the participant
  • Currently has a malignancy or has a history of malignancy within 3 years before screening (with the exception of localized basal cell carcinoma and/or squamous cell carcinoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study intervention administration or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first study intervention)
  • Is currently receiving systemic corticosteroids or other immunosuppressants for disorders unrelated to the pregnancy
  • Has received or planning to receive plasmapheresis, immunoadsorption therapy, intravenous immunoglobulin (IV Ig), or any immunoglobulin (Ig)G fragment crystallizable (Fc)-related protein therapeutics during the current pregnancy
  • Has a severe infection including opportunistic infections
  • Presence of abnormal (protocol-specified) hematologic lab values during screening
  • History of an unprovoked pulmonary embolism or history of recurrent deep vein thrombosis (DVT)

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Nipocalimab

Participants will receive nipocalimab intravenously (IV) once weekly (qw) from randomization through gestational age (GA) Week 35.

Nipocalimab will be administered as an intravenous infusion.

他の名前:
  • JNJ-80202135
  • M281
  • JNJ-86507083
プラセボコンパレーター:Placebo

Participants will receive matching placebo IV qw from randomization through GA Week 35.

Placebo will be administered as an intravenous infusion.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Pregnancies That did not Result in Fetal Loss, Intrauterine Transfusion (IUT), Hydrops Fetalis, or Neonatal Death
時間枠:From randomization in the study through 4 weeks of age or 41 weeks Postmenstrual Age (PMA) during neonatal period, whichever is later

Percentage of pregnancies that did not result in fetal loss, IUT, hydrops fetalis, or neonatal death (during the neonatal period) will be reported. Hydrops fetalis is defined as the presence of greater than or equal to(>=)2 abnormal fluid collections in the fetus or neonate, such as ascites, pleural effusions, pericardial effusion, and generalized skin edema (skin thickness greater (>)5 millimeter [mm]). PMA is the time elapsed between the first day of the last menstrual period and birth (gestational age) plus the time elapsed after birth (chronological age).

From randomization in the study through 4 weeks of age or 41 weeks Postmenstrual Age (PMA) during neonatal period, whichever is later

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants With Hemolytic Disease of the Fetus and Newborn (HDFN) by Severity
時間枠:For first database lock: from randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later for the first database lock; for second database lock: through 12 weeks after birth

Number of participants with HDFN by severity will be reported. The severity of HDFN is defined as: 5 (fatal): fetal or neonatal death due to any reason; 4 (severe): hydrops fetalis (in fetus or newborn) or receiving IUT during pregnancy as a result of HDFN but not 5 (fatal); 3 (moderate): neonatal exchange transfusions received as a result of HDFN related hemolysis and jaundice but not 4 (severe) or 5 (fatal); 2 (mild): neonatal simple transfusions received due to HDFN after birth, with or without phototherapy, but not 3 (moderate), 4 (severe), or 5 (fatal); and 1 (minimal or none): not in 2 (mild), 3 (moderate), 4 (severe), or 5 (fatal) as described above. Here database lock implies the last participant has given birth or terminated their pregnancy, completed the Week 4 visit after delivery, and whose neonate has also completed the Week 4 visit (or 41 weeks PMA, whichever is later) or died prior to this timepoint.

For first database lock: from randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later for the first database lock; for second database lock: through 12 weeks after birth
Time to First Occurrence of IUT or Hydrops Fetalis
時間枠:From randomization to delivery of baby (Up to 38 weeks)

Time to first occurrence of IUT or hydrops fetalis will be reported.

From randomization to delivery of baby (Up to 38 weeks)
Neonatal Mortality and Morbidity Index (NMMI) in Liveborn Neonates
時間枠:Through 38 weeks PMA or at discharge if earlier than 38 weeks PMA

The NMMI will be assessed with the following categories: fatal: fetal/neonatal death; major morbidity: any of intraventricular hemorrhage grade 3/4, seizures, hypoxic-ischemic encephalopathy, necrotizing enterocolitis stage 2/3, respiratory distress syndrome requiring mechanical ventilation, bronchopulmonary dysplasia requiring oxygen support, or persistent pulmonary hypertension; Minor morbidity: anemia requiring simple transfusion, hyperbilirubinemia requiring an exchange transfusion, hypotension requiring treatment, intraventricular hemorrhage grade 1/2, necrotizing enterocolitis stage 1, or respiratory distress syndrome not requiring mechanical ventilation; None: no major or minor morbidities described above. Hyperbilirubinemia requiring phototherapy will be classified in this category'

Through 38 weeks PMA or at discharge if earlier than 38 weeks PMA
Number of IUT's Received During the Pregnancy
時間枠:From randomization to delivery of baby (Up to 38 weeks)

Number of IUT's received during the pregnancy will be reported.

From randomization to delivery of baby (Up to 38 weeks)
Percentage of Pregnancies With Fetal Loss
時間枠:Time to delivery of baby (Up to 38 weeks)

Percentage of pregnancies with fetal loss will be reported.

Time to delivery of baby (Up to 38 weeks)
Percentage of Pregnancies With Fetal or Neonatal Death
時間枠:Through Week 4 or 41 weeks PMA

Percentage of pregnancies with fetal or neonatal death (through the neonatal period) as a result of HDFN will be reported.

Through Week 4 or 41 weeks PMA
Percentage of Pregnancies With Hydrops Fetalis
時間枠:Up to 41 weeks PMA

Percentage of pregnancies with hydrops fetalis will be reported. Hydrops fetalis is defined as the presence of >=2 abnormal fluid collections in the fetus or neonate, such as ascites, pleural effusions, pericardial effusion, and generalized skin edema (skin thickness >5 mm).

Up to 41 weeks PMA
Percentage of Pregnancies Receiving IUT During Pregnancy
時間枠:Up to 35 weeks of GA period

Percentage of pregnancies receiving IUT during pregnancy will be reported.

Up to 35 weeks of GA period
Gestational Age (GA) at First IUT
時間枠:Up to 35 weeks of GA period

GA at first IUT will be reported.

Up to 35 weeks of GA period
Percentage of Pregnancies Receiving >1 IUT During Pregnancy
時間枠:Up to 35 weeks of GA period

Percentage of pregnancies receiving >1 IUT during pregnancy will be reported.

Up to 35 weeks of GA period
Percentage of Pregnancies Receiving IUT or HDFN Resulting in Fetal Demise (Less Than) <GA Week 20
時間枠:Up to 20 weeks

Percentage of pregnancies receiving IUT or HDFN resulting in fetal demise <GA Week 20 will be reported.

Up to 20 weeks
Gestational Age at Delivery
時間枠:Up to 38 weeks

Gestational age at delivery will be reported.

Up to 38 weeks
Percentage of Pregnancies With Neonatal Death Through the Neonatal Period
時間枠:From randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later

Percentage of pregnancies with neonatal death through the neonatal period will be reported.

From randomization in the study through 4 weeks of age or 41 weeks PMA during neonatal period, whichever is later
Percentage of Liveborn Neonates With HDFN-related Morbidities Other Than Anemia and Hyperbilirubinemia or Jaundice
時間枠:From day of birth up to 4 weeks

Percentage of liveborn neonates with HDFN-related morbidities other than anemia and hyperbilirubinemia or jaundice will be reported.

From day of birth up to 4 weeks
Absolute Weight of Liveborn Neonates or Infants
時間枠:Up to 104 weeks

Absolute weight of liveborn neonates or infants will be reported.

Up to 104 weeks
Change From Baseline in Weight of Liveborn Neonates or Infants
時間枠:Baseline to up to 104 weeks

Change from baseline in weight of liveborn neonates or infants will be reported.

Baseline to up to 104 weeks
Liveborn Neonates Length of Stay in Neonatal Intensive Care Unit
時間枠:From day of birth up to 27 days

Liveborn neonates length of stay in neonatal intensive care unit will be reported.

From day of birth up to 27 days
Percentage of Liveborn Neonates Receiving Exchange Transfusions for HDFN
時間枠:From day of birth up to 27 days

Percentage of liveborn neonates receiving exchange transfusions for HDFN will be reported.

From day of birth up to 27 days
Number of Neonatal Exchange Transfusions per Liveborn Neonate
時間枠:From day of birth up to 27 days

Number of neonatal exchange transfusions per liveborn neonate will be reported.

From day of birth up to 27 days
Percentage of Liveborn Neonates or Infants with Simple Transfusions for HDFN
時間枠:For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks

Percentage of liveborn neonates or infants with simple transfusions for HDFN through the neonatal period (for the first database lock) or 12 weeks (for the second database lock) after birth will be reported.

For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks
Number of Simple Transfusions for HDFN per Liveborn Neonate or Infant
時間枠:For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks

Number of simple transfusions for HDFN per liveborn neonate or infant through the neonatal period (for the first database lock) or 12 weeks (for the second database lock) after birth will be reported.

For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks
Percentage of Liveborn Neonates With Hyperbilirubinemia Treated With Phototherapy
時間枠:From day of birth up to 27 days

Percentage of liveborn neonates with hyperbilirubinemia treated with phototherapy will be reported.

From day of birth up to 27 days
Number of Days of Phototherapy Received for Hyperbilirubinemia per Liveborn Neonate
時間枠:From day of birth up to 27 days

Number of days of phototherapy received for hyperbilirubinemia per liveborn neonate will be reported.

From day of birth up to 27 days
Percentage of Liveborn Neonates or Infants Receiving Intravenous Immunoglobulin (IVIg) for HDFN Treatment
時間枠:For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks

Percentage of liveborn neonates or infants receiving IVIg for HDFN treatment will be reported.

For first database lock: From birth up to 4 weeks; for second database lock: From birth up to 12 weeks
Number of Maternal Deaths
時間枠:Form randomization up to 24 weeks postpartum

Number of maternal deaths will be reported.

Form randomization up to 24 weeks postpartum
Number of Participants with Adverse Events (AEs)
時間枠:From randomization up to 24 weeks postpartum

Number of participants with AEs, serious adverse events, and AEs of special interest (AESIs), AE's leading to discontinuations, infections, serious infections, infusion reactions, and hypersensitivity reactions will be reported. Treatment-emergent adverse events associated with the following situations are considered as AESIs: hypoalbuminemia, clinically significant bleeding with a corresponding placental finding on ultrasound, maternal infections that led to clinically significant morbidities or mortalities in fetus or neonates, Infections that are severe or require intravenous (IV) anti-infective or operative or invasive intervention in maternal participants or neonates or infants, and infants with hypogammaglobulinemia.

From randomization up to 24 weeks postpartum
Number of Maternal Pregnancy Complications
時間枠:Up to 38 weeks

Number of maternal pregnancy complications will be reported.

Up to 38 weeks
Number of IUT Related complications
時間枠:Up to 35 weeks of GA period

Number of participants with IUT related complications will be reported.

Up to 35 weeks of GA period
Percentage of Pregnancies With Cesarean Delivery, Preterm Birth, Fetal Growth, and Preeclampsia
時間枠:Up to 38 weeks of GA period

Percentage of pregnancies with cesarean delivery, cesarean delivery due to IUT complications, preterm birth <GA week 28, preterm birth <GA week 32, preterm birth <GA week 34, preterm birth <GA week 37, fetal growth restriction, and preeclampsia will be reported.

Up to 38 weeks of GA period
Percentage of Liveborn Neonates or Infants Who Died
時間枠:Up to 104 weeks

Percentage of liveborn neonates or infants who died will be reported.

Up to 104 weeks
Percentage of Liveborn Neonates or Infants With AEs
時間枠:Up to 104 weeks

Percentage of liveborn neonates or infants with AEs, SAEs, AESIs, infections, serious infections will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Any event requiring hospitalization (or prolongation of hospitalization) that occurs during participation in the study must be reported as an SAE.

Up to 104 weeks
Percentage of Liveborn Neonates or Infants Receiving IVIg for Non-HDFN Indications
時間枠:Up to 104 weeks

Percentage of liveborn neonates or infants receiving IVIg for non-HDFN indications will be reported.

Up to 104 weeks
Percentage of Liveborn Neonates or Infants With Abnormal Hearing
時間枠:Up to 104 weeks

Percentage of liveborn neonates or infants with abnormal hearing will be reported.

Up to 104 weeks
Bayley Scales of Infant Development and Toddler Development
時間枠:Week 52 and 104

The Bayley Scales of infant development is considered the standard assessment of early child development and includes cognition, language, motor skills, social emotional, and adaptive behavior will be reported. The Bayley Scales (3rd edition) are reference standards that measure infant and toddler development in five areas: cognition, language, motor skills, social-emotional and adaptive behavior. The cognition, language and motor skills scales are directly administered to the infant, while social-emotional, and adaptive behavior scales are caregiver questionnaires. The scores are standardized using norm reference samples with representative demographics and age adjusted for prematurity. Higher scores in the Bayley Scales indicate better outcomes.

Week 52 and 104
Change From Baseline in Generalized Anxiety Disorder 7-Item (GAD7) Over time During Pregnancy and Postpartum
時間枠:Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum

Change from baseline in GAD7 over time during pregnancy and postpartum will be reported. The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. The recall period for all items is the past 2 weeks. Responses to all items are rated on a 4-point Likert scale ranging from 0 "not at all" to 3 "nearly every day". The total score ranges from 0 to 21, with higher scores indicating higher severity of anxiety symptoms.

Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Change From Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Domain Score
時間枠:Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum

Change from baseline in SF-36v2 acute form domain score will be reported. The SF-36 version 2 acute is a self-administered, 36-item questionnaire measuring health-related quality of life and includes 8 domains that measure physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality social functioning, role limitations due to emotional problems, and mental health. The 8 domains can be aggregated into 2 summary scales that reflect physical and mental health: a physical component summary and a mental component summary. Responses to all items are rated on a 3, 5, or 6-point Likert scale, with higher scores indicating better health status.

Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Change From Baseline in EuroQol Five-dimension Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS) Score
時間枠:Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum

Change from baseline in EQ-5D-5L visual analogue score will be reported. The EQ-5D descriptive system is comprised of 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain or discomfort and anxiety or depression. The EQ-5D-5L uses a 5-point Likert response scale ranging from "no problems" to "extreme problems", with higher scores indicating better quality of life. EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS). EQ-VAS score ranges from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state. Higher score indicates good health state.

Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Change From Baseline in EuroQol 5-Dimension Descriptive (EQ-5D) Index Score
時間枠:Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum

Change from baseline in EQ-5D index score will be reported. The EQ-5D descriptive system is comprised of 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain or discomfort and anxiety or depression. The EQ-5D-5L descriptive system uses a 5-point Likert response scale ranging from "no problems" to "extreme problems", with higher scores indicating better quality of life.

Baseline (Day 1) and Week 30 during pregnancy and Week 4 postpartum
Infant Health-Related Quality of Life Instrument (IQI) Score for Neonate or Infant Overtime
時間枠:Weeks 4, 8 and 52

IQI score for neonate or infant will be reported. The IQI consists of 7 health attributes including sleeping, feeding, breathing, stooling or poo, mood, skin, and interaction. Responses to all items are rated on a 4-point Likert scale, with higher scores indicating better quality of life.

Weeks 4, 8 and 52

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年12月20日

一次修了 (推定)

2027年8月5日

研究の完了 (推定)

2029年10月8日

試験登録日

最初に提出

2023年6月13日

QC基準を満たした最初の提出物

2023年6月13日

最初の投稿 (実際)

2023年6月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • CR109199
  • 2021-002359-12 (EudraCT番号)
  • 80202135EBF3001 (その他の識別子:Janssen Research & Development, LLC)
  • 2022-502629-16-00 (レジストリ識別子:EUCT number)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する